Lebeau B, Gence B, Bourdain M, Loria Y
Poumon Coeur. 1982 Mar-Apr;38(2):125-9.
Ketotifene is a new preventive treatment for asthma possessing the main advantage of being administered orally. Results were analyzed after treatment of 1 791 patients with allergic paroxysmal asthma, at a daily dose of 2 mg for a minimum duration of 3 months. Ketotifene was found to be effective both against asthma attacks (no further episodes in 30% of cases, and reduction in their frequency by at least a half in 35%), and by the fact that associated anti-asthma medication could be suppressed. Positive effects were noted after two weeks of treatment, with improvement increasing during the observation period (3 months). Tolerance was good, the principal side effect being somnolence (13% of cases), which occurred early in treatment but was reversible in more than one-third of these patients.
酮替芬是一种新型的哮喘预防性治疗药物，其主要优点是可口服给药。对1791例过敏性阵发性哮喘患者进行治疗，每日剂量2毫克，最短疗程3个月后对结果进行了分析。结果发现，酮替芬对哮喘发作有效（30%的病例未再发作，35%的病例发作频率至少降低一半），且可停用相关的抗哮喘药物。治疗两周后即观察到积极效果，在观察期（3个月）内改善情况不断增加。耐受性良好，主要副作用是嗜睡（13%的病例），嗜睡在治疗早期出现，但超过三分之一的患者可逆转。
